WHY CANNABINOIDS?
The use of cannabinoids for medical purposes dates back to more than 4000 years ago. Differently originated (plant-derived, synthetic-produced, endogenous-released), these molecules interact (although are not limited to) with cannabinoid receptors, which are part of the endocannabinoid system, a complex cell-signaling system that helps regulate the most critical body functions.
Studying cannabinoids is crucial for advancing medical science and health. Here we aim to put the endocannabinoid system at the center of renewed international research and drug development
CANNABINOID TRANSLATIONAL SCIENCE
FIRST SYMPOSIUM
FIRST SYMPOSIUM
CANNABINOIDS TRANSLATIONAL SCIENCE
01
By exploiting different areas (organic/medicinal/computational), the chemist can be considered the first pillar of the Route that drives research from the bench to the bedside. As a main actor, the chemist is the creator of new chemical entities that may become active drugs tackling diseases. By synthesizing ligands inspired by the reactivity of the molecules, aided by molecular docking and artificial intelligence algorithms, the chemist ultimately provides new strategies, more efficient and more stable, to combat diseases.
02
BIOCHEMIST
03
CLINICIAN
By exploiting different areas (medicine/pathology/pharmaceutical regulatory), the clinical physician can be considered the third pillar of the Route that drives research from the bench to the bedside. As a main actor, the clinical physician leads clinical trials by adopting the chemical entities as a possible new therapy. By supporting ground-breaking research into new treatments ensuring patient safety, the clinical physician pioneers the next generation of medicines, and ultimately provides evidence to approve a drug on the market.
SPEAKERS
Brendan Hughes
Brendan Hughes (British) has been working at EMCDDA/EUDA since 2001 in the field of national drug legislation, after gaining a Masters degree in International Criminal Law (LLM) specialising in narcotics law.
Mauro Maccarrone
Mauro Maccarrone is a Professor of Biochemistry at the University of L’Aquila, Italy, and Head of the Lipid Neurochemistry Unit at the European Center for Brain Research in Rome.
Colin Stott
Colin Stott is the COO of Phytanix Bio.
He is the former Research & Operations Director (from 2001 to 2017) and International Scientific Affairs Director of GW Pharmaceuticals (from 201701 to 2019) and was closely involved in the development and approval of the cannabinoid medicines Sativex® and Epidiolex® / Epidyolex®.
Geoffrey Guy
Professor Guy founded GW Pharmaceuticals plc in 1998, a world leader in cannabinoid therapeutics, and was Chairman until its sale in May 2021.
Andrea Chicca
Andrea holds a Ph.D. in Pharmacology with over 15 years of experience. He was appointed Adjunct Professor at the University of Bern’s Medical Faculty and completed a Master of Advanced Studies in Translational Medicine and Biomedical Entrepreneurship.
Franjo Grotenhermen
Franjo Grotenhermen graduated in medicine and earned his doctorate in Cologne, specializing in internal medicine, surgery, and naturopathy.
Jose Martinez-Orgado
Born in Madrid, Spain, he earned his M.D. from the Complutense University of Madrid (UCM) in 1985 and his Ph.D. from the Autónoma University of Madrid (UAM) in 1999.
Saoirse O’Sullivan
Professor Saoirse Elizabeth O’Sullivan (@ScienceSaoirse) received her doctorate from Trinity College Dublin in 2001 and moved to the University of Nottingham in 2002 as a Research fellow where she began researching cannabinoid pharmacology.
Vincenzo Di Marzo
Dr. Vincenzo Di Marzo is the Canada Excellence Research Chair on the Microbiome-Endocannabinoidome Axis in Metabolic Health (CERC-MEND) at Laval University, Quebec, and Associate Research Director at the Institute of Biomolecular Chemistry, National Research Council (ICB-CNR), Italy.
George Kunosk
George Kunos is a Senior Investigator at the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and serves as Chief of the Laboratory of Physiologic Studies.
THE AID-CARE PROJECT
THE AID-CARE PROJECT
